2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2669

Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Abstract Number: 2671

PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Abstract Number: 2672

Ultrasonography in the Diagnosis of Giant Cell Arteritis
Abstract Number: 2673

Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Abstract Number: 2674

Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis
Abstract Number: 2675

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Abstract Number: 2676

Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Abstract Number: 2678

Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms
Abstract Number: 2679

Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Abstract Number: 2680

Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
Abstract Number: 2681

Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Abstract Number: 2682

Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution
Abstract Number: 2683

Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].